Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer

BACKGROUND: Immune checkpoint inhibitors (ICI) have become first-line treatment for metastatic colorectal cancer (CRC) with deficient mismatch repair (dMMR). Despite the remarkable response reported in preliminary trials, the role of ICI in patients with early-stage, operable CRC remains unclear. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Veen, Torhild, Kanani, Arezo, Lea, Dordi, Søreide, Kjetil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491705/
https://www.ncbi.nlm.nih.gov/pubmed/37528319
http://dx.doi.org/10.1007/s00262-023-03480-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491705/
https://www.ncbi.nlm.nih.gov/pubmed/37528319
http://dx.doi.org/10.1007/s00262-023-03480-w

Ejemplares similares